- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01555112
Safety and Efficacy Study to Test Topical AS101 for External Genital Warts
A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Human papillomavirus (HPV)-induced condyloma acuminata (CA), commonly known as anogenital or genital warts, is among the most common sexually transmitted diseases. There are a wide variety of available treatments of genital warts, but none are considered completely effective. It has been suggested that AS101 works by stimulating the innate and acquired arms of the immune system.
In previous proof-of-concept clinical study AS101 topical cream was tested on HPV warts and shown cure in high percentages. However the cream formulation was unstable therefore a new formulation was developed mainly for the carrier. In this study the improved AS101 ointment will be tested in female patients with external genital warts in an open study to assess its safety and efficacy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Afula, Israel
- Gynecology department, Haemek MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women 18 years of age and in good health;
- Must sign an ethics committee approved informed consent form and be able to adhere to study visits and protocol requirements;
- Women must agree to avoid sexual contact while the ointment is on their skin;
- All study participants who are sexually active must use a barrier protection method of contraception such as condom in addition to another birth control measure such as oral contraceptives, intrauterine device, spermicide or surgical sterilization during treatment and for 60 days after completion of treatment;
- Patients with first clinical diagnosis of external genital warts, in the external genitalia including vulva (labia minora and majora), inguinal folds, pubic area, perineum, perianal, or buttocks areas;
- A minimum of one lesion and a maximum of 10 lesions identified at study entry, and the maximum diameter of the largest wart is no larger than 10 mm;
- Papanicolaou smears must be obtained in all females within 12 months of Day 1 and be negative for evidence of high grade intraepithelial neoplasia. Women with high grade intraepithelial neoplasia on cytology will be eligible if subsequent colposcopy with biopsy of suspicious area is negative for high grade squamous intraepithelial lesions (Grade 2 or 3). Atypia, HPV effect, and low grade intraepithelial lesions (Grade 1) are acceptable.
Exclusion Criteria:
- Participation in an investigational trial within 30 days prior to Day 1;
- Use of systemic steroids within 30 days of Day 1;
- Previous participation in a trial investigating AS101 for any indication.
- Any prior treatment for genital warts prior to participation;
- Topical and systemic immunosuppressive or immunomodulatory medications (including corticosteroids) within 30 days prior Day 1, and while on study;
- Known history of HIV, HBV and HCV viral infection.
- Current active infection with herpes genitalis or history of herpes genitalis infection within the last 30 days prior to Day 1 (patients on long-term suppressive antiviral therapy are eligible);
- Current and/or recurrent pathologically relevant genital infections other than genital warts;
- Diagnosis of high-grade cervical dysplasia;
- Internal anogenital, vaginal, urethral and cervical warts requiring treatment;
- Chronic or acute skin condition that might interfere with the evaluation of the treatment or study drug effect;
- Cutaneous surgery, including cryosurgery, to genital area within 30 days of Day 1;
Screening laboratory tests results from a complete blood count (CBC), chemistry panel, urine pregnancy test and urinalysis obtained during screening (Day -14 to Day 0):
- Must be within the site laboratory's defined normal reference ranges, and/or according to the Investigator's decision;
- Urine pregnancy test in females of childbearing potential must be negative;
- Inadequate renal function: Serum Creatinine > 2.0mg/dL (> 2.0 ULN);
- Inadequate liver function: Serum (total) Bilirubin > 2 mg/dl or ALT and/or AST greater than two times the upper limit of the reference range.
- Uncontrolled infection or acute severe febrile illness;
- Diagnosed as having uncontrolled autoimmune disease;
- Pregnant or lactating;
- Current drug or alcohol abuse that may interfere with the objectives of the study;
- Known allergy to AS101 or any component of the investigational formulation;
- Subjects with any other clinically significant medical condition, psychiatric condition or laboratory abnormality which would, in the judgment of the Investigator, interfere with the subject's ability to participate in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topical AS101
15% AS101 ointment applied twice a day for treatment of external genital warts.
|
AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of patients with Adverse Events and their severity
Time Frame: up to 16 weeks
|
up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to complete clearance
Time Frame: 16 weeks
|
16 weeks
|
Number of patients with complete and partial clearance of external genital warts
Time Frame: 16 weeks
|
16 weeks
|
Number of warts that were completely or partially cleared
Time Frame: 16 weeks
|
16 weeks
|
Recurrence rate in treatment area
Time Frame: 3 months follow up
|
3 months follow up
|
Time to recurrence
Time Frame: 3 months follow up
|
3 months follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shabtai Romano, MD, Ha'Emek Medical Center, Afula, Israel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Papillomavirus Infections
- Skin Diseases, Viral
- Tumor Virus Infections
- Warts
- Condylomata Acuminata
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Protective Agents
- Adjuvants, Immunologic
- Radiation-Protective Agents
- Ammonium trichloro(dioxoethylene-O,O'-)tellurate
Other Study ID Numbers
- AS101-IL#001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Condyloma Acuminata
-
Hospices Civils de LyonCompleted
-
Laboratorio Elea Phoenix S.A.TerminatedRecurrent Condyloma | Nonrecurrent CondylomaArgentina
-
G&E Herbal Biotechnology Co., LTDCompletedGenital Warts | Condylomata Acuminata | Condyloma Acuminata | Venereal WartsTaiwan
-
Merck Sharp & Dohme LLCCompletedCondyloma Acuminata | Anogenital Human Papilloma Virus InfectionJapan
-
Merck Sharp & Dohme LLCCompletedCondyloma Acuminata | Anogenital Human Papilloma Virus Infection
-
Lisen Arnheim DahlstromMerck Sharp & Dohme LLCCompleted
-
VaxartCompletedCondylomaArgentina, Chile, Ecuador, Serbia
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
Gilead SciencesCompletedHIV Infections | Condyloma AcuminataUnited States
-
University of California, San FranciscoRecruitingWarts | Condylomata Acuminata | Human Papilloma Virus | Warts, Genital | CondylomaUnited States
Clinical Trials on Topical AS101
-
Universidad de AntioquiaINNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES... and other collaboratorsWithdrawnLeishmaniasis, CutaneousColombia
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Stanford UniversityUniversity of Pennsylvania; University of California, Davis; Oregon Health and... and other collaboratorsRecruiting
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCutaneous T Cell LymphomaUnited States
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Taro Pharmaceuticals USACompletedScalp PsoriasisUnited States
-
University Hospitals Coventry and Warwickshire...University Hospital, GenevaTerminatedTopical Corticosteroid-treated Dermatology Patients | Intra-ocular PressureUnited Kingdom
-
Amazentis SAproDERM GmbHCompleted
-
Amazentis SAproDERM GmbHCompletedErythema | Skin Inflammation | Sun Damaged SkinGermany